Cara Therapeutics reported $2.13M in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US USD 2.41M 277K
Acelrx Pharmaceuticals ACRX:US USD 569K 307K
Cara Therapeutics CARA:US USD 2.13M 925K
Chugai Pharma 4519:JP JPY 212.91B 143.81B
Depomed DEPO:US USD 5.91M 1.9M
Endo International Ordinary Shares ENDP:US USD 176.86M 1.06M
Halozyme Therapeutics HALO:US USD 42.12M 5.2M
Horizon Pharma HZNP:US USD 240.79M 6.65M
Johnson & Johnson JNJ:US USD 7.76B 29M
Neurocrine Biosciences NBIX:US USD 7.7M 1.6M
Pacira Pharmaceuticals PCRX:US USD 61.92M 11.24M
Pfizer PFE:US USD 9.82B 3.73B
Revance Therapeutics RVNC:US USD 23.52M 12.78M
Supernus Pharmaceuticals SUPN:US USD 22.95M 2.92M
Teva Pharmaceutical Industries TEVA:US USD 1.78B 101M
Vanda Pharmaceuticals VNDA:US USD 6.24M 82K